What is Sinusitis Drugs Market Scope?
Sinusitis drugs or medicines are used for sinus infection or rhinosinusitis which is caused due to the inflammation of the sinuses creating other issues and symptoms like the plugged nose, pain in the face, thick nasal mucus headache,m fever, sore throat, and others. Drugs range such as analgesics, antibiotics, antihistamines, corticosteroids, decongestants, sulphonamides is consumed for sinus. These sinusitis drugs are prescribed according to the sinus infection which ranges from acute or chronic sinusitis.
The Sinusitis Drugs market study is being classified by Type (Analgesics, Antibiotics, Antihistamines, Corticosteroids, Decongestants and Sulphonamides), by Application (Acute Sinusitis and Chronic Sinusitis) and major geographies with country level break-up.
Sanofi S.A. (France), Pfizer Inc. (United States), Novartis International AG (Switzerland), Johnson & Johnson (United States), Merck & Co., Inc. (United States), AstraZeneca plc (United Kingdom), Amgen Inc. (United States) and Teva Pharmaceutical Industries Ltd. (Israel) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Sinusitis Drugs market by Type, Application and Region.
On the basis of geography, the market of Sinusitis Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
On 6th August 2020, Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) as add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with INC does not provide adequate disease control1. Phase III studies have shown that Xolair reduces nasal polyp size (defined by Nasal Polyp Score; NPS) and improves symptoms and quality of life in patients with CRSwNP5. Xolair is the first treatment for CRSwNP specifically targeting and blocking immunoglobulin E (IgE), a key driver in the inflammatory pathway of this disease.
"Dupixent is the first FDA approved medicine for adults with chronic rhinosinusitis with nasal polyposis, and the only approved therapy has shown to shrink nasal polyp size and also improve the signs and symptoms of the associated chronic rhinosinusitis."
Influencing Market Trend
- Continuous Research and Development in the Sinusitis Drugs
- Increasing Consumption of Analgesics and Antibiotics as Sinusitis Drugs
- Rising Prevalence of Sinus Infection Among Different Range of People
- Need for Treating the Sinus Infection and Other Health Problems Associated with it
- Surging Awareness about the Regular Checkups will Boost the Sinusitis Drugs Market
- Side Effects Associated with the Consumption of Sinusitis Drugs
- Stiff Competition due to New Entrants in the Sinusitis Drugs Market
Key Target Audience
Sinusitis Drugs Manufacturers, Sinusitis Drugs International Traders, Sinusitis Drugs Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.